{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T17:08:31Z","timestamp":1698080911381},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[1989,1,1]],"date-time":"1989-01-01T00:00:00Z","timestamp":599616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1989]]},"DOI":"10.1007\/bf00647239","type":"journal-article","created":{"date-parts":[[2004,11,28]],"date-time":"2004-11-28T06:05:28Z","timestamp":1101621928000},"page":"S45-S48","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2"],"prefix":"10.1007","volume":"23","author":[{"given":"Takafumi","family":"Ichida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Miyagiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Nohzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Ichida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/bjc.1983.15","volume":"47","author":"C Bindon","year":"1983","unstructured":"Bindon C, Czerniecki M, Ruell P, Edward A, McCarthy WH, Harris R, Hersey P (1983) Clearance rates and systemic effects of intravenously administrated interleukin-2 (IL-2) containing preparations in human subjects. Br J Cancer 47: 123","journal-title":"Br J Cancer"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.4049\/jimmunol.130.5.2203","volume":"130","author":"JH Donoue","year":"1983","unstructured":"Donoue JH, Rosenberg SA (1983) The fate of interleukin-2 after in vivo administration. J Immunol 130: 2203","journal-title":"J Immunol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1084\/jem.155.6.1823","volume":"155","author":"EA Grimm","year":"1982","unstructured":"Grimm EA, Mazunder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823","journal-title":"J Exp Med"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/291335a0","volume":"291","author":"CS Henny","year":"1981","unstructured":"Henny CS, Kuribayashi K, Kern D, Gills S (1981) Interleukin-2 augments natural killer cell activity. Nature 291: 335","journal-title":"Nature"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJM198405313102204","volume":"310","author":"HA Liebman","year":"1984","unstructured":"Liebman HA, Furie BC, Tong MJ (1984) Des-?-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310: 1427 N Engl J Med 310: 1427","journal-title":"N Engl J Med"},{"key":"CR6","first-page":"4420","volume":"41","author":"MT Lotze","year":"1981","unstructured":"Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA (1981) Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41: 4420","journal-title":"Cancer Res"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4049\/jimmunol.134.1.157","volume":"134","author":"MT Lotze","year":"1985","unstructured":"Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA (1985) In vivo administration of purified human interleukin-2. 1. Half-life and immunologic effects of the Jurkat cell line-derived interleukin-2. J Immunol 134: 157","journal-title":"J Immunol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/1097-0142(19840215)53:4<896::AID-CNCR2820530414>3.0.CO;2-E","volume":"53","author":"A Mazumder","year":"1984","unstructured":"Mazumder A, Eberlein TJ, Grimm EA, Wilson DJ, Keenan AM, Aamodt R, Rosenberg SA (1984) Phase 1 study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 53: 896","journal-title":"Cancer"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1084\/jem.159.2.495","volume":"159","author":"A Mazumder","year":"1984","unstructured":"Mazumder A, Rosenberg SA (1984) Successful immunotherapy of natural killer resistant established pulmonary melanoma metastasis by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J Exp Med 159: 495","journal-title":"J Exp Med"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","volume":"193","author":"DA Morgan","year":"1976","unstructured":"Morgan DA, Rusetti FW, Gallo RC (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007","journal-title":"Science"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/1097-0142(19860901)58:5<1001::AID-CNCR2820580502>3.0.CO;2-K","volume":"58","author":"K Okuno","year":"1986","unstructured":"Okuno K, Takagi H, Nakamura T, Nakamura Y, Iwasa Z, Yasutomi M (1986) Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer 58: 1001","journal-title":"Cancer"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0065-230X(08)60637-5","volume":"25","author":"SA Rosenberg","year":"1977","unstructured":"Rosenberg SA, Terg WD (1977) Passive immunotherapy of cancer in animals and man. Adv Cancer Res 25: 323","journal-title":"Adv Cancer Res"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.6367046","volume":"223","author":"SA Rosenberg","year":"1984","unstructured":"Rosenberg SA, Grimm EA, McGrogan M (1984) Biological activity of recombinant human interleukin-2 produced inEscherichia coli. Science 223: 1412","journal-title":"Science"},{"key":"CR14","first-page":"501","volume":"3","author":"SA Rosenberg","year":"1984","unstructured":"Rosenberg SA (1984) Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Response Mod 3: 501","journal-title":"J Biol Response Mod"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shilori E, Vetto JM, Seipp CA, Simpson C, Reichert CM (1985) Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485","journal-title":"N Engl J Med"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","volume":"316","author":"SA Rosenberg","year":"1987","unstructured":"Rosenberg SA, Lotze ML, Muul LM, Chang AE, Avis FP, Leitman S, Linehan M, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889","journal-title":"N Engl J Med"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/302305a0","volume":"302","author":"T Taniguchi","year":"1983","unstructured":"Taniguchi T, Matsui H, Fujita T, Takaoka C, Kishima N, Yoshimoto R, Hamuro J (1983) Structure and expression of a cloned cDNA for human interleukin-2. Nature 302: 305","journal-title":"Nature"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/284278a0","volume":"284","author":"H Wagner","year":"1980","unstructured":"Wagner H, Hardt C, Heeg K, Rollinghoff M, Pfizenmaier K (1980) T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu\/nu mice. Nature 284: 278","journal-title":"Nature"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM198704093161502","volume":"316","author":"WH West","year":"1987","unstructured":"West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898","journal-title":"N Engl J Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00647239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00647239\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00647239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T14:39:55Z","timestamp":1682865595000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00647239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989]]},"references-count":19,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1989]]}},"alternative-id":["BF00647239"],"URL":"https:\/\/doi.org\/10.1007\/bf00647239","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989]]}}}